Newsletter | August 2, 2021

08.02.21 -- Site-Specific, Controlled Drug-Protein Conjugation

Advancements In Antibody-Drug Conjugates (ADCs) Using SMARTag Technology

SMARTag technology enables site-specific, controlled drug-protein conjugation, and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.

Keys To A Successful Rapid Commercial Launch

For new biologics and drug development, the quicker a company can get its product to patients, the better. Combining a rapid launch following regulatory approval with effective messaging and post-launch services can provide a competitive advantage.

Ensuring A Consistent, High-Quality Biologic

Gain insights on risk mitigation, the difference between innovator and biosimilar drug product process development, and what to expect from the development and manufacturing partner during the process development phase.